back to Australia directory
australia clinical guidance

Progestogen-only pill (POP): traditional, desogestrel, drospirenone

A detailed Australian summary of progestogen-only pill (pop): traditional, desogestrel, drospirenone, with source-attributed priorities, a practical workflow, safety escalation and state or territory implementation boundaries.

JurisdictionAustralia
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceHealthcare professionals practising in Australia
This is an iatroX educational summary of named Australia sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Apply current TGA product information, PBS restrictions, state or territory law, local referral criteria, formulary and antimicrobial policy. A national recommendation does not create uniform service access.

Scope

Clarify pregnancy possibility, breastfeeding, bleeding pattern, breast cancer, liver disease, interacting medicines and ability to take a daily pill reliably. Explain differences between traditional and newer progestogen-only pills, including their Australian missed-pill windows and ovulation suppression. This summary is limited to the population, decisions and escalation boundaries stated in the named source.
sources for this section:RANZCOG contraception

The Bottom Line

  • Clarify pregnancy possibility, breastfeeding, bleeding pattern, breast cancer, liver disease, interacting medicines and ability to take a daily pill reliably.
  • Explain differences between traditional and newer progestogen-only pills, including their Australian missed-pill windows and ovulation suppression.
  • Traditional norethisterone and desogestrel or drospirenone formulations have different missed-pill instructions and cannot share one advice sheet.
  • Use current product information for start, switching, missed doses and enzyme-inducer management rather than applying one rule to every formulation.
sources for this section:RANZCOG contraception

Practical clinical workflow

1

Topic-specific assessment action

Clarify pregnancy possibility, breastfeeding, bleeding pattern, breast cancer, liver disease, interacting medicines and ability to take a daily pill reliably.
2

Topic-specific diagnostic action

Use current product information for start, switching, missed doses and enzyme-inducer management rather than applying one rule to every formulation.
3

Topic-specific management action

Counsel that irregular bleeding is common and does not imply harm, but assess persistent new bleeding, pain or pregnancy symptoms.
4

Topic-specific follow-through

Enzyme-inducing antiseizure medicines can reduce pill effectiveness and favour an unaffected long-acting method.
sources for this section:RANZCOG contraception

Safety boundaries and escalation

  • Suspected ectopic pregnancy, severe abdominal pain, heavy bleeding, thrombotic symptoms or serious hepatic disease requires urgent assessment.
  • Breastfeeding is generally compatible, but postpartum start and pregnancy exclusion still follow the Australian handbook.
sources for this section:RANZCOG contraception

Implementation

The named source is national or binational guidance used in Australia, but referral access, public-health directions, formularies and funded services can still differ by state, territory and health service. Check current TGA product information for medicines. Offer culturally safe care and use the NACCHO鈥揜ACGP National Guide where Aboriginal and Torres Strait Islander preventive or chronic-care recommendations differ.
sources for this section:RANZCOG contraception

Clinical use boundary

This independently written summary is not an official guideline. Check the linked source version, current TGA-approved product information where medicines are involved, and the applicable state, territory and local pathway at the point of care.

sources for this section:RANZCOG contraception

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Royal Australian and New Zealand College of Obstetricians and GynaecologistsContraception (C-Gyn 3)C-Gyn 3 路 Version 7.2, September 2024; review due March 2029 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Australia question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.